The de novo design and synthesis of cyclic urea inhibitors of factor Xa: Initial sar studies

Bioorganic and Medicinal Chemistry Letters

Volumn 8, Issue 19, 1998, Pages 2705-2710

  Galemmo Jr , Robert A ^a   Maduskuie, Thomas P ^a   Dominguez, Celia ^a,b   Rossi, Karen A ^a   Knabb, Robert M ^a   Wexler, Ruth R ^a   Stouten, Pieter F W ^a  

^a DUPONT COMPANY   (United States)

^b AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [(1 ACETIMIDOYL 3 PYRROLIDINYL)OXY]PHENYL] 3 (7 AMIDINO 2 NAPHTHYL)PROPIONIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; BLOOD CLOTTING; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; THROMBOSIS;

BINDING SITES; DRUG DESIGN; FACTOR XA; HYDROGEN BONDING; IMIDAZOLES; KINETICS; PROTEIN CONFORMATION; PYRIMIDINONES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP; UREA;

OXY;

EID: 0032491225     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(98)00471-5     Document Type: Article

References (26)

1. 1 Yamazaki, M. Drug Future 1995, 20, 911; Claeson, G. Blood Coagul. Fibrin. 1994, 5, 411.
2. 1 Yamazaki, M. Drug Future 1995, 20, 911; Claeson, G. Blood Coagul. Fibrin. 1994, 5, 411.
3. 2 Morishima, Y.; Tanabe, K.; Terada, Y.; Hara, T.; Kunitada, S. Thromb. Haemostasis 1997, 78, 1366; Cadroy, Y.; Harker, L.A.; Hanson, S.R. J. Lab. Clin. Med. 1989, 114, 349.
4. 2 Morishima, Y.; Tanabe, K.; Terada, Y.; Hara, T.; Kunitada, S. Thromb. Haemostasis 1997, 78, 1366; Cadroy, Y.; Harker, L.A.; Hanson, S.R. J. Lab. Clin. Med. 1989, 114, 349.
5. 3 Meade, T.W.; Brennan, P.J.; Wilkes, H.C.; Zuhrie, S.R. Lancet 1998, 351, 233; Vorchheimer, D.A..; Fuster, V. J. Thromb. Thrombolysis 1995, 2, 171.
6. 3 Meade, T.W.; Brennan, P.J.; Wilkes, H.C.; Zuhrie, S.R. Lancet 1998, 351, 233; Vorchheimer, D.A..; Fuster, V. J. Thromb. Thrombolysis 1995, 2, 171.
7. 4 Bona, R.D.; Hickey, A.D.; Wallace, D.M. Thromb. Haemost. 1997, 78, 137.
8. 5 Sturzebecher, J.; Sturzebecher, U.; Vieweg, H.; Wagner, G.; Hauptmann, J.; Markwardt, F. Thromb. Res. 1989, 54, 245
9. 6 Nagahara, T.; Yokoyama, Y.; Inamura, K.; Katakura, S.-I.; Komoriya, S.; Yamaguchi, H.; Hata, T.; Iwamoto, M. J. Med. Chem. 1994, 37, 1200; For a review see: Kunitada, S.; Nagahara, T. Curr Pharm Des 1996, 2, 531.
10. 6 Nagahara, T.; Yokoyama, Y.; Inamura, K.; Katakura, S.-I.; Komoriya, S.; Yamaguchi, H.; Hata, T.; Iwamoto, M. J. Med. Chem. 1994, 37, 1200; For a review see: Kunitada, S.; Nagahara, T. Curr Pharm Des 1996, 2, 531.
11. 7 Quan, M.L.; Pruitt, J.R.; Ellis, C.D.; Liauw, A.Y.; Galemmo, Jr, R.A.; Stouten, P.F.W.; Wityak, J.; Knabb, R.M.; Thoolen, M.J.; Wong, P.C.; Wexler, R.R. Bioorg. Med. Chem. Lett. 1997, 7, 2813.
12. 8 Maduskuie, T.P.; McNamara, K.J.; Ru, Y.; Knabb, R.M.; Stouten, P.F.W. J. Med. Chem. 1998, 41, 53.
13. 9 Quan M.L., Design and synthesis of isoxazoline derivatives as factor Xa inhibitors, 215th American Chemical Society National Meeting (MEDI 202) 29 Mar 1998; Pinto D.J.P.; Quan M.L.; Fevig, J.M.; Pruitt, J.R.; Ellis, C.D.; Orwat, M.; Wang, S.; Liauw, A.Y.; Wong, P.C.; Knabb, R.M.; Thoolen, M.J.; Wexler, R.R., Isoxazoline derivatives as potent factor Xa inhibitors, 215th American Chemical Society National Meeting (MEDI 119) 29 Mar 1998.
14. 9 Quan M.L., Design and synthesis of isoxazoline derivatives as factor Xa inhibitors, 215th American Chemical Society National Meeting (MEDI 202) 29 Mar 1998; Pinto D.J.P.; Quan M.L.; Fevig, J.M.; Pruitt, J.R.; Ellis, C.D.; Orwat, M.; Wang, S.; Liauw, A.Y.; Wong, P.C.; Knabb, R.M.; Thoolen, M.J.; Wexler, R.R., Isoxazoline derivatives as potent factor Xa inhibitors, 215th American Chemical Society National Meeting (MEDI 119) 29 Mar 1998.
15. 10 Klein, S.I.; Czekaj, M.; Gardner, C.J.; Guertin, K.R.; Cheney, D.L.; Spada, A.P.; Bolton, S.A.; Brown, K.; Colussi, D.; Heran, C.L.; Morgan, S.R.; Leadley, R.J.; Dunwiddle, C.T.; Perrone, M.H.; Chu, V. J. Med. Chem. 1998, 41, 437.
16. 11 Pinner, A. In Die Imidoaether und ihre Derivate, Oppenheim, Ed.; Berlin, 1892; pp 1-85.
17. 12 Tulinsky, A.; Padmanbhan, K.; Padmanbhan, K.P.; Park, C.H.; Bode, W.; Huber, R.; Blankenship, D.T.; Cardin, A.D.; Kisiel, W. J. Mol. Biol. 1993, 232, 947.
18. 21 as implemented in the Affinity program (MSI). The low energy model was assumed to be the most probable binding mode.
19. 14 Burley, S.K.; Petsko, G.A. FEBS Lett. 1986, 203, 139.
20. 15 For a recent report of fXa inhibitors employing a cyclic urea functionality: Chou, Y.-L.; Guilford, W.J.; Koovakkat, S.; Mohan, R.; Wu, S.C.; Liang, A.; Trinh, L.; Morrissey, M.M., Design, synthesis and biological activity of novel Factor Xa Inhibitors. 10. Optimization of dibenzyl cyclic urea analogs, 215th American Chemical Society National Meeting (MEDI 130) 29 Mar 1998.
21. 16 Lam, P.Y.S.; Jadhav, P.K.; Eyermann, C.J.; Hodge, C.N.; Ru, Y.; Bacheler, L.; Meek, J.; Otto, M.J.; Rayner, M.; Wong, N.; Chang, C.-H.; Weber, P.C.; Jackson, D.A.; Sharpe, T.; Erickson-Vitanen, S. Science, 1994, 263, 380.
22. 17 Cram, D.J.; Lam, P.Y.S. Tetrahedron 1986, 42, 1607.
23. i determination: Kettner, C.; Mersinger, L.; Knabb, R.M. J. Biol Chem. 1990, 265, 18289.
24. 19 Burley, S.K.; Petsko, G.A. In Adv. Protein Chem., Academic, San Diego, 1988; Vol 39, pp 125.
25. 20 Bode, W.; Turk, D.; Karshikov, A.J. Protein Science 1992, 1, 426.
26. 21 Luty, B.A.; Wasserman, Z.R.; Stouten, P.F.W.; Hodge, C.N.; Zacharias, M.; McCammon, J.A. J. Comp. Chem. 1995, 16, 454.